Traws Pharma Inc. has announced the initiation of two Phase 2 clinical studies evaluating ratutrelvir, a ritonavir-free antiviral treatment for COVID-19. The first study is a non-inferiority trial comparing ratutrelvir to PAXLOVID®, assessing safety, efficacy, rates of disease rebound, and incidence of Long COVID. The second is a single-arm trial evaluating safety and efficacy in patients who are ineligible for PAXLOVID®, a group considered at higher risk for poor outcomes and with limited treatment options. Top-line data from both trials are expected by year-end 2025. No study results have been presented yet.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-098994), on October 14, 2025, and is solely responsible for the information contained therein.